-
Henlius Biotech’s HanBeiTai sBLA Accepted for HCC Treatment Review
•
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that a supplementary Biologic License Application (sBLA) for its HanBeiTai, a biosimilar of Roche’s Avastin (bevacizumab), has been accepted for review by the Center for Drug Evaluation (CDE). The targeted indication is hepatocellular carcinoma (HCC). Drug BackgroundHanBeiTai is also awaiting a regulatory decision…
-
Alphamab Oncology Doses First Patient in KN046-209 Study for NSCLC
•
China-based Alphamab Oncology (HKG: 9966) announced the first patient dosing in the multi-center, open-label Phase II KN046-209 study. The trial evaluates the efficacy, safety, and tolerability of KN046 (erfonrilimab) combined with axitinib in first-line locally advanced or metastatic PD-L1-positive (TPS ≥ 1%) non-small cell lung cancer (NSCLC) patients who have…
-
Roche’s Rozlytrek Wins NMPA Approval for ROS1+ NSCLC Treatment
•
Swiss pharmaceutical giant Roche’s China unit announced that it has received market approval from the National Medical Products Administration (NMPA) for its drug Rozlytrek (entrectinib). The approved indication is for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug BackgroundEntrectinib, the first ROS1 inhibitor with…
-
EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs
•
US-based pharma EQRx Inc. (Nasdaq: EQRX) has revealed its latest plans to accelerate the US market development of two innovative drugs licensed from Chinese partners. The company’s Q2 2022 financial report shows that a US-led Phase IIIb bridging study has recently been initiated for aumolertinib as a first-line treatment of…
-
Novartis Aims for China to Be Second – Largest Market by 2024
•
Dan Brindle, head of Novartis AG’s (NYSE: NVS) China operations, recently spoke with Xinhua news service about the company’s ambitions in the Chinese market. Brindle expects China to become the multinational corporation’s “second-largest market by 2024.” This goal will be achieved through a series of new product approvals. “In the…
-
ESR Group Enters Life Sciences with Zhangjiang NEO Acquisition
•
Hong Kong-based real estate asset manager ESR Group Ltd (HKG: 1821) has made its first investment in the life sciences sector by acquiring an R & D business park in Shanghai’s Zhangjiang Hi-Tech Development Zone. The 8,940 sq. m. site, named Zhangjiang NEO, was purchased for RMB268 million (USD39.8 million).…
-
ClouDr Partners with Ipsen to Expand Diphereline’s Reach in China
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), known as “ClouDr,” has partnered with French pharmaceutical company Ipsen S.A. (Euronext: IPN; ADR: IPSEY) regarding Ipsen’s Diphereline (triptorelin), a natural gonadotropin-releasing hormone (GnRH) agonist analog. Financial details of the partnership were not disclosed. ClouDr is a one-stop chronic disease management…
-
E-Health Now Raises Funds for Oncology and Cardiovascular Digital Health Products
•
E-Health Now, a Beijing-based commercial insurance-focused health management service solutions provider, has raised an undisclosed amount of funds in a Series A++ financing round. The round was led by Borchid Capital, with participation from Tongji Fund. The proceeds will be used for the research and development of specialty digital health…
-
KingYee and XINSEC IOT Form Strategic Partnership for Smart Ward Solutions
•
Shanghai-based KingYee, a leading domestic intelligent medical technology and service provider, has entered into a strategic investment and collaboration agreement with XINSEC IOT, a medical internet of things (IoT) application specialist based in Guangdong. KingYee will invest in XINSEC, and the two companies will work together on the creation of…
-
Chongqing Pharscin’s Gabexate Mesylate Passes GQCE as First Generic in China
•
China-based Chongqing Pharscin Pharmaceutical Co., Ltd (SHE: 002907) announced that its gabexate mesylate has passed the generic quality consistency evaluation (GQCE), making it the first generic version of the drug to achieve this status in China. The drug is used to treat acute mild (edematous) pancreatitis and as adjuvant therapy…
-
Bennu Biotherapeutics Raises Over RMB100m in Angel+ Round for Global Pipeline Development
•
Shanghai-based cell therapy specialist Bennu Biotherapeutics has raised over RMB100 million (USD14.8 million) in an angel+ financing round. The round was led by INCE Capital and included contributions from Life Science Park Innovation Investment Fund and Witruth Capital. The proceeds will be used to advance the pre-clinical and clinical development…
-
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
•
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced that its randomized, double-blind, placebo-controlled, multi-dose escalation and dose exploration Phase II clinical study for the anti-IL-17A monoclonal antibody (mAb) SSGJ-608 in moderate to severe plaque psoriasis has reached its primary endpoint. Study DetailsThe study,…
-
Zelgen Biopharmaceuticals’ Donafenib Receives NMPA Approval for Thyroid Cancer
•
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that the supplementary New Drug Application (sNDA) for its Category 1 anti-cancer drug donafenib in locally advanced / metastatic radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) has been approved by the National Medical Products Administration (NMPA). This is the second indication approval for…
-
Siemens Healthineers Q3 2022 Results Show Decline Amid COVID-19 Impact
•
Siemens Healthineers AG (ETR: SHL) released its financial results for the fiscal year Q3 2022 period ending June 30. The company reported global revenues of EUR5,186 million (USD5,279 million) over the three months, marking a 5.7% year-on-year (YOY) decline in constant currency terms. This decline was primarily attributed to a…
-
Chinese Researchers Map Cancer Genomic Alterations in 10,000 Patients
•
A team of Chinese researchers led by Wang Minghui at Sun Yat-sen University has conducted deep next-generation DNA sequencing (NGS) on tumor tissues and matched blood specimens from over 10,000 patients in China using a 450-gene comprehensive assay. The study provides a comprehensive comparison of somatically altered genes, the distribution…
-
Longwood Valley Medtech Partners with J&J MedTech on Digital Surgery Biosystem
•
Beijing-based Longwood Valley Medtech has entered into an in-depth partnership with US major Johnson & Johnson MedTech. The two companies will explore digital innovation, product development, marketing, brand promotion, and more. Their goal is to bolster intelligent and precise clinical solutions for orthopedics and surgeries and create a patient-oriented digital…
-
Elite Pharma Raises RMB100m in Series B Financing for Drug Delivery Tech
•
Shanghai-based Elite Pharmaceutical Technology Inc. has reportedly raised nearly RMB100 million (USD14.8 million) in a Series B financing round, led by Innoval Capital. Hefei Industry Investment and Hefei Innovation Investment also participated in the round. The proceeds will be used for research and development, clinical trials, and the construction of…
-
WuXi ATU Licenses TESSA Technology to Janssen Biotech for AAV Production
•
WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec, has entered into a licensing agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. Facilitated by Johnson & Johnson Innovation, the deal allows Janssen Bio to utilize WuXi ATU’s TESSA technology and gain…
-
Medlander Medical Technology’s IPO Raises RMB 1 billion on Shanghai’s STAR Board
•
Medlander Medical Technology Inc., a leading Chinese manufacturer of pelvic floor rehabilitation equipment, has completed an initial public offering (IPO) of 25 million shares priced at RMB40.29 on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The listing has raised RMB 1 billion (USD148.3 million) for the firm. Company BackgroundFounded…
-
InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma
•
InnoCare Pharma (HKG: 9969) announced that a supplemental New Drug Application (sNDA) for its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib has been accepted for review by the Center for Drug Evaluation (CDE). The Chinese firm is seeking a new indication for patients with relapsed or refractory marginal zone lymphoma. Drug…
